The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research

Markus Borner, A Roth, Damien Dietrich et al.|Journal of Clinical Oncology|2004

Cited by 9